The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Giorgio Vittorio Scagliotti

Department of Clinical and Biological Sciences

University of Turin

Torino

Italy

[email]@unito.it

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Department of Clinical and Biological Sciences, University of Turin, Torino, Italy. 2012
  • University of Turin, San Luigi Hospital, Orbassano (Turin), Italy. 2012
  • University of Turin, Department of Clinical and Biological Sciences, Azienda Ospedaliera S. Luigi, Regione Gonzole 10. 2003 - 2012

References

  1. Zoledronic acid in patients with stage IIIA/B NSCLC: results of a randomized, phase III study. Scagliotti, G.V., Kosmidis, P., de Marinis, F., Schreurs, A.J., Albert, I., Engel-Riedel, W., Schallier, D., Barbera, S., Kuo, H.P., Sallo, V., Perez, J.R., Manegold, C. Ann. Oncol. (2012) [Pubmed]
  2. Tasisulam sodium (LY573636 sodium) as third-line treatment in patients with unresectable, metastatic non-small-cell lung cancer: a phase-II study. Scagliotti, G.V., Ilaria, R., Novello, S., von Pawel, J., Fischer, J.R., Ermisch, S., de Alwis, D.P., Andrews, J., Reck, M., Crino, L., Eschbach, C., Manegold, C. J. Thorac. Oncol (2012) [Pubmed]
  3. Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer. Scagliotti, G.V., Novello, S., Schiller, J.H., Hirsh, V., Sequist, L.V., Soria, J.C., von Pawel, J., Schwartz, B., Von Roemeling, R., Sandler, A.B. Clin. Lung. Cancer (2012) [Pubmed]
  4. Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Phase III Trial. Scagliotti, G.V., Krzakowski, M., Szczesna, A., Strausz, J., Makhson, A., Reck, M., Wierzbicki, R.F., Albert, I., Thomas, M., Miziara, J.E., Papai, Z.S., Karaseva, N., Thongprasert, S., Portulas, E.D., von Pawel, J., Zhang, K., Selaru, P., Tye, L., Chao, R.C., Govindan, R. J. Clin. Oncol. (2012) [Pubmed]
  5. Randomized Phase III Study of Surgery Alone or Surgery Plus Preoperative Cisplatin and Gemcitabine in Stages IB to IIIA Non-Small-Cell Lung Cancer. Scagliotti, G.V., Pastorino, U., Vansteenkiste, J.F., Spaggiari, L., Facciolo, F., Orlowski, T.M., Maiorino, L., Hetzel, M., Leschinger, M., Visseren-Grul, C., Torri, V. J. Clin. Oncol. (2012) [Pubmed]
  6. Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer. Scagliotti, G., Govindan, R. Oncologist (2010) [Pubmed]
  7. A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer. Scagliotti, G.V., Germonpré, P., Bosquée, L., Vansteenkiste, J., Gervais, R., Planchard, D., Reck, M., De Marinis, F., Lee, J.S., Park, K., Biesma, B., Gans, S., Ramlau, R., Szczesna, A., Makhson, A., Manikhas, G., Morgan, B., Zhu, Y., Chan, K.C., von Pawel, J. Lung. Cancer (2010) [Pubmed]
  8. Nonsmall cell lung cancer in never smokers. Scagliotti, G.V., Longo, M., Novello, S. Curr. Opin. Oncol (2009) [Pubmed]
  9. The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial. Scagliotti, G.V., De Marinis, F., Rinaldi, M., Crinò, L., Gridelli, C., Ricci, S., Zhao, Y.D., Liepa, A.M., Peterson, P., Tonato, M. J. Thorac. Oncol (2009) [Pubmed]
  10. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Scagliotti, G., Hanna, N., Fossella, F., Sugarman, K., Blatter, J., Peterson, P., Simms, L., Shepherd, F.A. Oncologist (2009) [Pubmed]
  11. Updated clinical information on multitargeted antifolates in lung cancer. Scagliotti, G.V., Ceppi, P., Capelletto, E., Novello, S. Clin. Lung. Cancer (2009) [Pubmed]
  12. New data integrating multitargeted antifolates into treatment of first-line and relapsed non-small-cell lung cancer. Scagliotti, G.V., Selvaggi, G. Clin. Lung. Cancer (2008) [Pubmed]
  13. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. Scagliotti, G.V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., Lee, J.S., Mellemgaard, A., Park, K., Patil, S., Rolski, J., Goksel, T., de Marinis, F., Simms, L., Sugarman, K.P., Gandara, D. J. Clin. Oncol. (2008) [Pubmed]
  14. Emerging drugs for mesothelioma. Scagliotti, G.V., Selvaggi, G. Expert. Opin. Emerg. Drugs (2007) [Pubmed]
  15. Optimizing chemotherapy for patients with advanced non-small cell lung cancer. Scagliotti, G. J. Thorac. Oncol (2007) [Pubmed]
  16. Potential role of multi-targeted tyrosine kinase inhibitors in non-small-cell lung cancer. Scagliotti, G.V. Ann. Oncol. (2007) [Pubmed]
  17. Can advanced non-small-cell lung cancer be treated with weekly instead of 3-weekly docetaxel? Scagliotti, G.V. Nat. Clin. Pract. Oncol (2006) [Pubmed]
  18. Antimetabolites and cancer: emerging data with a focus on antifolates. Scagliotti, G.V., Selvaggi, G. Expert. Opin. Ther. Pat (2006) [Pubmed]
  19. Current status of adjuvant chemotherapy in NSCLC. Scagliotti, G.V., Novello, S. Ann. Oncol. (2006) [Pubmed]
  20. The place of targeted therapies in the management of non-small cell bronchial carcinoma. Target therapies in lung cancer management. Scagliotti, G.V., Selvaggi, G. Rev. Mal. Respir (2006) [Pubmed]
  21. Pemetrexed plus carboplatin or oxaliplatin in advanced non-small cell lung cancer. Scagliotti, G.V. Semin. Oncol. (2005) [Pubmed]
  22. The ALPI Trial: the Italian/European experience with adjuvant chemotherapy in resectable non-small lung cancer. Scagliotti, G.V. Clin. Cancer Res. (2005) [Pubmed]
  23. A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956). Scagliotti, G.V., Smit, E., Bosquee, L., O'Brien, M., Ardizzoni, A., Zatloukal, P., Eberhardt, W., Smid-Geirnaerdt, M., de Bruin, H.G., Dussenne, S., Legrand, C., Giaccone, G. Lung. Cancer (2005) [Pubmed]
  24. Which should be added to cisplatin for advanced non-small-cell lung cancer--vinorelbine or gemcitabine?. Scagliotti, G.V. Nature Clinical Practice. Oncology (2005) [Pubmed]
  25. Pemetrexed: a new cytotoxic agent in the development for first-line non-small-cell lung cancer. Scagliotti, G.V. Lung. Cancer (2005) [Pubmed]
  26. Current development of adjuvant treatment of non-small-cell lung cancer. Scagliotti, G.V., Novello, S. Clin. Lung. Cancer (2004) [Pubmed]
  27. Pemetrexed in front-line chemotherapy for advanced non-small-cell lung cancer. Scagliotti, G.V., Novello, S., Crino, L., Rosell, R. Oncology (Williston Park, N.Y.) (2004) [Pubmed]
  28. Docetaxel in combined-modality treatment of inoperable locally or regionally advanced lung cancer. Scagliotti, G.V., Douillard, J.Y. Lung. Cancer (2004) [Pubmed]
  29. Adjuvant therapy in completely resected non-small-cell lung cancer. Scagliotti, G.V., Novello, S. Curr. Oncol. Rep (2003) [Pubmed]
  30. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. Scagliotti, G.V., Fossati, R., Torri, V., Crinò, L., Giaccone, G., Silvano, G., Martelli, M., Clerici, M., Cognetti, F., Tonato, M. J. Natl. Cancer Inst. (2003) [Pubmed]
 
WikiGenes - Universities